Qurse Revand compared with placebo for metabolic dysfunction-associated steatotic liver disease
Tests Qurse Revand against a placebo in adults with metabolic dysfunction-associated steatotic liver disease.
Plain-language title generated from the registry record
Registry title: Qurse Revand for MASLD: A Randomized Controlled Safety and Efficacy Trial
Key facts
- Where
- Bangalore, IndiaSee the site
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 20 and 60 years old?
Source: NCT07902219, who can take part
Where in India
- National Institute of Unani Medicine BangaloreBangalore, IndiaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- National Institute of Unani Medicine, Bengaluru
- Trial code
- NCT07902219
- Record updated
- 28 October 2026
- Original description
This study is a randomized, double-blind, placebo-controlled clinical trial designed to evaluate the safety, efficacy of the Unani compound formulation Qurse Revand compared to a placebo in adult participants with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).Read full original descriptionShow less
Evaluation of Safety and Efficacy of Qurse Revand in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Randomized Double-Blind Placebo-Controlled Clinical Trial
This study is a randomized, double-blind, placebo-controlled clinical trial designed to evaluate the safety, efficacy of the Unani compound formulation Qurse Revand compared to a placebo in adult participants with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).
Inclusion: Diagnosed Cases of Fatty Liver (Grade Ⅰ \&Ⅱ) by USG; Participants with Presence of at least 1or more cardiometabolic risk factor; Excess adiposity (BMI of ≥25 kg/m², Waist circumference of ≥94 cm in men and ≥80 cm in women); Disorders of glucose metabolism (Prediabetes- HbA1c (5.7% to 6.4 %), FPG- 100 to 125 mg/dL, Type 2 diabetes mellitus- HbA1c of ≥6.5%; FPG of ≥126 mg/dL); Hypertriglyceridemia (Plasma triglycerides ≥150 mg/dL); High-density lipoprotein (HDL) cholesterol: <40 mg/dL in men or ≤50 mg/dL in women; Arterial hypertension: Resting blood pressure of 130/85 mm Hg or greater or ongoing antihypertensive treatment; Participants with minimal or no alcohol intake (i.e. <20 g/day for females and <30 g/day for males); Participants of any gender, aged between 20-60yrs.
Exclusion: Participants on medications causing steatosis (Amiodarone, Valproic Acid, Methotrexate, Tamoxifen, Glucocorticoids); Known History of Hepatitis, Liver Cancer, systemic disorders like Malignancies, cardiovascular diseases; Pregnant And Lactating Mother; Fatty Liver Grade Ⅲ (by USG).